

Dear Shaun

Thank you for sending on the ACD for lapatinib. Our comments are as follows:

i) Do you consider that all of the relevant evidence has been taken into account?

YES

ii) Do you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence, and that the preliminary views on the resource impact and implications for the NHS are appropriate?

YES

iii) Do you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS?

YES

iv) Are there any equality related issues that need special consideration that are not covered in the ACD?

NO

We have the following additional comment: one of the bullet points under 3.11 is confusing by using commas for decimals in currency i.e. separating pounds from pence (see below) - suggest replacing with full stops

"The cost for administering chemotherapy infusion for trastuzumab changed from £207,22 per infusion used in the manufacturer submission to £117,00 per infusion based on a published assessment report for a previous appraisal."

Thanks,

██████████, on behalf of the SHTAC team

---

Delivered via MessageLabs

---